Molbio Diagnostics has been awarded the KOCHON Prize 2024 by the Stop TB Partnership, recognizing its pioneering work in ensuring access to cutting-edge diagnostic tools and innovation in the fight against tuberculosis (TB). This distinction makes Molbio the first private company globally—and the third Indian entity after ICMR and Dr. L.S. Chauhan—to receive the prestigious award.
Goa-based Molbio Diagnostics, backed by Temasek and MOPE, has filed its DRHP with SEBI for an IPO comprising a fresh issue of ₹200 crore and an OFS of 1.25 crore equity shares. The funds will be utilized for R&D infrastructure, manufacturing expansion, and corporate purposes.
With over 190,000 undiagnosed TB cases annually, the Philippines is turning to Indian innovation to close the gap. Through Molbio Diagnostics' WHO-endorsed Truenat® systems and portable X-ray solutions, the country is enhancing its ability to screen, diagnose, and treat TB—especially in remote and underserved communities.
